People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Platelet BioGenesis, Inc. | — | Other | Series B | $72.9M | $427.0M | 2017 |
| Phoenicis Therapeutics, Inc. | — | Pharmaceuticals | Series A | $23.8M | $38.6M | 2025 |
Philip Reilly at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Philip Reilly on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark De Souza | 1 | 10 |
| Mark P. De Souza | 1 | 7 |
| Mark McDade | 1 | 5 |
| Steven Altschuler | 1 | 5 |
| Richard Murray | 1 | 5 |
| Peter Finn | 1 | 5 |
| John Parker | 1 | 4 |
| Chidozie Ugwumba | 1 | 3 |
| Jonathan Thon | 1 | 2 |
| Steve Altschuler | 1 | 2 |
| Alexander Silver | 1 | 1 |
| Hal Landy | 1 | 1 |
| Joff Masukawa | 1 | 1 |
| Deborah Ramsdell | 1 | 1 |
| Joseph Italiano | 1 | 1 |
| Sam Rasty | 1 | 1 |
| Peter Erik Finn | 1 | 1 |
| Sven Karlsson | 1 | 1 |
| Sven Erik Karlsson | 1 | 1 |
| Jonathan Erik Thon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.